Navigation Links
Reportlinker Adds Top 10 Drug Delivery Technologies (2010 - 2015)
Date:9/28/2010

NEW YORK, Sept. 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Top 10 Drug Delivery Technologies (2010 - 2015)

http://www.reportlinker.com/p0304769/Top-10-Drug-Delivery-Technologies-2010---2015.html

Global Top 10 Drug Delivery Technologies Market (2008 – 2015)

The increasing demand for effective delivery of novel biopharmaceuticals is driving the growth of the global top 10 drug delivery technologies market. Further, patent expirations of drugs is also boosting market growth. The global top 10 drug delivery technologies market is expected to grow from $43.8 billion in 2009 to $81.5 billion in 2015, at an estimated CAGR of 11% from 2010 to 2015. The time release technologies market commands the largest share of the overall top 10 drug delivery technologies market owing to immense popularity of once-daily formulations.

Unconventional modes of drug delivery such as pulmonary, nasal and transdermal are gaining a lot of popularity especially in chronic disease conditions such as diabetes, hypertension, CNS and cancer. Nanotechnology advances have led to the development of innovative drug delivery systems.

Scope of the reportThis research report categorizes the global market top 10 drug delivery technologies on the basis of their growth, therapeutic areas, patents registered, and industry focus. The report analyzes geography; forecasting revenues and trends in each of the following submarkets:

  • Time release technologies
  • Targeted delivery
  • Aerosol technology
  • Encapsulation technology
  • Topical formulations
  • Injectables
  • Trandermal patch
    '/>"/>

  • SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Reportlinker Adds Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets
    2. Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
    3. Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile
    4. Reportlinker Adds Genzyme Corporation: PharmaVitae Profile
    5. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
    6. Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets
    7. Reportlinker Adds Actelion Ltd: PharmaVitae Profile
    8. Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
    9. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    10. Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile
    11. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... NEW YORK and RALEIGH, N.C., Oct. 20, ... the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced ... develop drug candidates for the treatment of the ... BioPontis Alliance announced its alliance model ... is a first demonstration of a collaborative model ...
    (Date:10/18/2014)... , Oct. 18, 2014  In a ... Campaign (HRC), the nation,s largest lesbian, gay, bisexual ... the use of Truvada for Pre-Exposure Prophylaxis (PrEP). ... used to prevent the spread of a disease ... only brand name anti-HIV drug combination currently approved ...
    (Date:10/17/2014)... Conn. , Oct. 17, 2014 UBM Medica ... a leading online community and information resource for neurologists ... disease and Alzheimer disease , with discussions of ... to 1 million Americans have Parkinson disease , more ... dystrophy, or Lou Gehrig disease. Diagnosis can be ...
    Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
    ... secondary endpoints support outcomes benefitHAYWARD, Calif., May ... held biopharmaceutical company developing anti-inflammatory drugs, announced ... events with Near-term Cardiovascular Inflammation Suppression), a ... of 500mg of varespladib when administered to ...
    ... Food Variety and Cognition-Related Fatty Acid are Important ... The strong preference kids with autism have ... nutritional deficiencies because their diets lack sufficient variety, ... Center at this year,s Pediatric Academic Societies meeting ...
    Cached Medicine Technology:Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome 2Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome 3Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome 4Lack of Food Variety Puts Kids With Autism at Risk for Poor Nutrition 2Lack of Food Variety Puts Kids With Autism at Risk for Poor Nutrition 3
    (Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
    (Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
    (Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today announced ... module enables easy administration and routing of follow-up items ... This application allows users such as Therapists to assign ... item to a specific client, categorize tasks the way ... for follow-ups. It's designed to enable easy access ...
    (Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
    (Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
    Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
    ... variations that point to spectrum disorders , TUESDAY, March ... for brain proteins that seem to be linked to ... of the most comprehensive genetic analyses of association between ... spectrum disorder] risk," said Anthony Monaco, of the Wellcome ...
    ... ... Detox Protocol using Far Infrared. FIR therapy is a major key for returning us back ... ... Ph.D., RIET-1, a Doctor of Integrative Medicine and an Industrial Toxicologist, has dedicated a ...
    ... complications, costs, , TUESDAY, March 30 (HealthDay News) -- Current ... age 45, especially for those who are overweight, but new ... 30 and 45 for everyone . , When screening ... every year to five years, the average cost per quality-adjusted ...
    ... lung cancer per year in Germany are due to ... in the current edition of Deutsches rzteblatt International ... and his coauthors ( Dtsch Arztebl Int 2010; ... the results of relevant studies, the recently published S1 ...
    ... One in three South Asian, West Asian or Arab women ... say they have trouble accessing a doctor to address ... findings, from a new study by researchers at St. Michael,s ... finds this group and immigrant women and men are at ...
    ... ... Misunderstandings about proper use of antibiotics have the potential to ... report in the April issue of AJIC: American Journal of Infection ... Control and Epidemiology, Inc. (APIC). esearchers from Columbia University and MixedInk ...
    Cached Medicine News:Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 2Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 3Health News:Diabetes Screening Should Start Sooner 2Health News:Diabetes Screening Should Start Sooner 3Health News:Minority women least likely to gain access to a doctor, study says 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 3Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 4Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 5
    Used to introduce large devices for vascular intervention....
    Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
    Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
    Used to introduce balloon, electrode, closed or non-tapered end and other catheters....
    Medicine Products: